What is synergy testing in AST, and when is it considered?

• A. Tests multiple drugs sequentially to find the best single agent.
• B. Measuring time to bacterial kill.
• C. Evaluates whether drug combinations exhibit greater activity than single agents; used for difficult infections or when monotherapy is unlikely to be effective.
• D. Assessing patient symptom improvement.

Answer: (C)

Synergy testing in antimicrobial susceptibility testing looks at how drugs interact when used together. The idea is to see whether a combination of antibiotics produces greater bacterial inhibition or killing than either agent alone, which is what “synergy” means in this context. This approach matters because some infections—especially those caused by difficult or resistant organisms—may not respond to a single drug, and a beneficial interaction can improve outcomes or help overcome resistance.

Clinically, synergy testing is considered for hard-to-treat infections, such as those caused by multidrug-resistant organisms, persistent biofilm-associated infections, or scenarios where monotherapy is unlikely to be effective. It helps guide whether a combination therapy could be more effective than the best single agent, potentially allowing lower doses or broader activity while balancing toxicity.

Common methods include checkerboard assays and time-kill studies, with interpretation often based on metrics like the fractional inhibitory concentration index. A synergistic interaction typically means the combination lowers the effective concentration needed for inhibition more than expected from the individual drugs, while non-synergistic or antagonistic results suggest little or negative added benefit from combining agents.